Notable Call Buying Activity in Teva Pharma (TEVA) Continues -Susquehanna
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
'Bullish Options Flow' in Teva Pharma (TEVA) Continues -Susquehanna
December 1, 2017 2:42 PM ESTSusquehanna options strategist Alison Edwards notes continued bullish options flow in Teva Pharma (NYSE: TEVA), as investors sold 5k Dec 14 Calls at $1.83 closing to buy 7k Dec 15 Calls $for 1.10, opening. Trading makes investor long ~30k Dec 156 calls. Also today, investors bought 13k Jan 17.5... More
Teva Pharma (TEVA) PT Raised to $16 at Mizuho Securities on Announced Major Cost Cuts
November 29, 2017 6:45 AM ESTMizuho Securities raised its price target on Teva Pharma (NYSE: TEVA) to $16.00 (from $12.00) while maintaining a Neutral rating, following a model update fueled by conversations with management.
Analyst Irina Koffler notes a positive outlook on the shares, following conversations with management... More
Teva Pharma (TEVA) Announces New Organization Structure, Leadership Changes
November 27, 2017 9:03 AM ESTTeva Pharmaceutical Industries Ltd. (NYSE & TASE: TEVA) announced today a new organization and leadership structure aimed to achieve better commercial focus and drive value creation. The new structure will enable strategic alignment across the portfolio, across regions and between functions, leveraging scale, enhancing agility, extracting efficiencies and providing increased proximity to the markets. This new structure will be implemented effective immediately.
... More
Teva Pharma (TEVA) Says It Isn't Planning to Divest Oncology/Pain Assets, Reassessed Situation - Bloomberg
November 27, 2017 8:27 AM ESTTeva Pharma (NYSE: TEVA) Says It Isn't Planning to Divest Oncology/Pain Assets, Reassessed Situation - Bloomberg
... More